大葉大學圖書館 |

登入

回首頁

Mechanisms of Fecal Microbiota Trans...

University of Minnesota.

Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
書名/作者:	Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection.
作者:	Weingarden, Alexa Rachel.
面頁冊數:	255 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-03(E), Section: B.
Contained By:	Dissertation Abstracts International77-03B(E).
標題:	Microbiology.
ISBN:	9781339135380
摘要、提要註:	Clostridium difficile infection is the most common nosocomial infection in the US and other developed countries, yet standard antibiotic therapy for this infection fails to cure nearly a quarter of patients. These individuals experience a recurrence of the infection, and a large subset of patients with a single recurrence go on to develop recurrent C. difficile infection syndrome (R-CDI), characterized by vicious cycles of repeated antibiotic use and recurrence of disease. Although fecal microbiota transplantation (FMT) is now widely recognized as an extremely effective therapy for R-CDI, its mechanisms were heretofore unknown. This substantial gap in our knowledge limited both our ability to design novel therapies for R-CDI and our understanding of the role our native intestinal microbes play in our health.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3728172

Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection.
Weingarden, Alexa Rachel.

Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection. - 255 p.

Source: Dissertation Abstracts International, Volume: 77-03(E), Section: B.

Thesis (Ph.D.)--University of Minnesota, 2015.

Clostridium difficile infection is the most common nosocomial infection in the US and other developed countries, yet standard antibiotic therapy for this infection fails to cure nearly a quarter of patients. These individuals experience a recurrence of the infection, and a large subset of patients with a single recurrence go on to develop recurrent C. difficile infection syndrome (R-CDI), characterized by vicious cycles of repeated antibiotic use and recurrence of disease. Although fecal microbiota transplantation (FMT) is now widely recognized as an extremely effective therapy for R-CDI, its mechanisms were heretofore unknown. This substantial gap in our knowledge limited both our ability to design novel therapies for R-CDI and our understanding of the role our native intestinal microbes play in our health.

ISBN: 9781339135380Subjects--Topical Terms:

182563
Microbiology.

Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection.
LDR:02825nam a2200289 4500 001 441010
005 20160422125046.5
008 160525s2015 ||||||||||||||||| ||eng d
020 $a 9781339135380
035 $a (MiAaPQ)AAI3728172
035 $a AAI3728172
040 $a MiAaPQ $c MiAaPQ
100 1 $a Weingarden, Alexa Rachel. $3 630083
245 1 0 $a Mechanisms of Fecal Microbiota Transplantation and Development of Novel Therapies for Clostridium difficile Infection.
300 $a 255 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-03(E), Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisers: Michael J. Sadowsky; Alexander Khoruts.
502 $a Thesis (Ph.D.)--University of Minnesota, 2015.
520 $a Clostridium difficile infection is the most common nosocomial infection in the US and other developed countries, yet standard antibiotic therapy for this infection fails to cure nearly a quarter of patients. These individuals experience a recurrence of the infection, and a large subset of patients with a single recurrence go on to develop recurrent C. difficile infection syndrome (R-CDI), characterized by vicious cycles of repeated antibiotic use and recurrence of disease. Although fecal microbiota transplantation (FMT) is now widely recognized as an extremely effective therapy for R-CDI, its mechanisms were heretofore unknown. This substantial gap in our knowledge limited both our ability to design novel therapies for R-CDI and our understanding of the role our native intestinal microbes play in our health.
520 $a The work herein summarizes our efforts to identify and test the mechanisms behind this important treatment. Our findings indicate that fecal bile acid composition, which is significantly altered following FMT, also dramatically impacts C. difficile physiology. Bile acids present after FMT, compared to those present prior to the procedure, prevent germination of C. difficile spores and limit the growth of vegetative cells. With this knowledge, we demonstrated that a bile acid already clinically available, ursodeoxycholic acid (UDCA), can also prevent C. difficile germination and growth. Although unfortunately UDCA is a poor treatment option for many patients due to its absorption in the small intestine, we showed both that a non-absorbed derivative of UDCA, C7-sulfated UDCA, may be a promising novel therapy for R-CDI, and that UDCA may still have clinical utility in patients with altered gastrointestinal anatomy. These findings have paved the way for novel treatments for this widespread infection.
590 $a School code: 0130.
650 4 $a Microbiology. $3 182563
690 $a 0410
710 2 $a University of Minnesota. $b Microbiology, Immunology and Cancer Biology. $3 630084
773 0 $t Dissertation Abstracts International $g 77-03B(E).
790 $a 0130
791 $a Ph.D.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3728172

筆 0 讀者評論

多媒體

多媒體檔案
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3728172

評論

新增評論分享你的心得

Export

取書館別